EIDD-2749

EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2 . EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus ( LCMV ). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses In Vitro EIDD-2749 induces a delayed stalling of phosphodiester bond formation by RSV and SARS-CoV-2 RdRP. EIDD-2749 is rapidly anabolizes, metabolically stable, and potently antiviral in disease-relevant well-differentiated HAE cultures. EIDD-2749 shows a ≥17-fold increase in anti-RSV potency relative to that on HEp-2 cells; however, the low cytotoxicity levels remains unchanged (CC 50 169 mM), resulting in a high SI (SI = EC 50 /CC 50 ) of ≥1877. EIDD-2749 inhibits SARS-CoV-2 with an EC 50 value of 0.2-0.6 M. EIDD-2749 has an EC 50 of 1.86 μM in theVero E6 cell line, cytotoxicity with a CC 50 of 380 μM, and stability in human plasma. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo EIDD-2749 (0.2, 1, 5 mg/kg; p.o.; single daily for 4 days) shows good orally efficacious in RSV infection mice model in a dose-dependent manner . EIDD-2749 shows high efficacious to SARS-CoV-2 infection and is effective with a single daily dose versus molnupiravir administered twice daily in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/cJ mice (RSV infection model) . Dosage: 0.2, 1, 5 mg/kg Administration: Oral administration; single daily for 4 days Result: Resulted in a statistically significant reduction in lung virus load. Form:Solid IC50& Target:RdRp, RSV,SARS-CoV-2, HCV, COVID-19, LCMV, .

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet